Protocol Ledger

NCT05506176 · Phase II/III · COMPLETED

A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19

Interventional Phase II/III clinical trial protocol NCT05506176 sponsored by Jiangsu Simcere Pharmaceutical Co in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-08-19 Enrollment: 1,208 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05506176
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,208 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05506176
Protocol FieldVerified Registry Value
NCT IdentifierNCT05506176
Consolidated Lead SponsorJiangsu Simcere Pharmaceutical Co
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment1,208 participants (ACTUAL)
Registered Start Date2022-08-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05506176
Hospital Research SiteLocationSite Profile
The First Affiliated Hospital of Xiamen UniversityXiamen, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI